Cullinan Therapeutics Inc
CGEM
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.3B
Close$
$1.45
91.4% downside
Current Fair Value
91.4% downsideOvervalued by 91.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.30 Billion |
|---|---|
| Enterprise Value | $1.22 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.72 |
| Beta | -0.01 |
| Outstanding Shares | 61,493,000 |
Return
| Return on Equity | -63.62% |
|---|---|
| Return on Assets | -56.27% |
| Return on Invested Capital | -69.08% |
Valuation & Multiples
| P/E Ratio | -6.26 |
|---|---|
| PEG | 26.8 |
| Price to Sales | - |
| Price to Book Ratio | 3.37 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -5.46 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
$3.67 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.84
Average shareholder expectationRevenue Estimate
$2.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7454▲ 45.60% |
|---|---|
| Total Calls | 185,000▼ 8.78% |
| Total Puts | 137,900▲ 134.92% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 117.28%▲ 6.54% |
|---|---|
| Total Invested | $1.31B▲ 41.01% |
| Investors Holding | 193▲ 16.00% |
ESG Score
No data
About Cullinan Oncology Inc
24 employeesCullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build a pi...